Equities analysts forecast that C.R. Bard, Inc. (NYSE:BCR) will post earnings of $3.09 per share for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for C.R. Bard’s earnings. The highest EPS estimate is $3.10 and the lowest is $3.08. C.R. Bard reported earnings of $2.77 per share during the same quarter last year, which would suggest a positive year over year growth rate of 11.6%. The firm is expected to issue its next earnings report on Thursday, January 25th.

On average, analysts expect that C.R. Bard will report full-year earnings of $11.89 per share for the current financial year, with EPS estimates ranging from $11.86 to $11.90. For the next fiscal year, analysts forecast that the business will report earnings of $12.98 per share, with EPS estimates ranging from $12.66 to $13.32. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for C.R. Bard.

C.R. Bard (NYSE:BCR) last announced its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $3.02 EPS for the quarter, topping the Zacks’ consensus estimate of $2.96 by $0.06. The business had revenue of $989.80 million for the quarter, compared to analyst estimates of $990.64 million. C.R. Bard had a net margin of 14.75% and a return on equity of 48.28%. The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.64 earnings per share.

A number of analysts have recently commented on BCR shares. Cowen reissued a “hold” rating and issued a $317.00 price objective on shares of C.R. Bard in a research report on Friday, November 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of C.R. Bard in a research report on Thursday, October 26th. Jefferies Group reaffirmed a “hold” rating and set a $317.00 price target on shares of C.R. Bard in a research report on Thursday, September 14th. ValuEngine lowered shares of C.R. Bard from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Finally, Barclays upped their price target on shares of C.R. Bard from $245.00 to $337.00 and gave the stock an “equal weight” rating in a research report on Monday, November 6th. One analyst has rated the stock with a sell rating, eight have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Hold” and an average target price of $305.00.

In other C.R. Bard news, VP Frank Lupisella, Jr. sold 9,173 shares of the company’s stock in a transaction on Wednesday, October 18th. The shares were sold at an average price of $325.00, for a total value of $2,981,225.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Sharon M. Luboff sold 30,252 shares of the company’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $320.00, for a total transaction of $9,680,640.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 224,139 shares of company stock worth $73,481,664. Corporate insiders own 0.80% of the company’s stock.

Several large investors have recently added to or reduced their stakes in BCR. Farallon Capital Management LLC acquired a new position in shares of C.R. Bard in the second quarter valued at about $463,101,000. Alpine Associates Management Inc. acquired a new position in shares of C.R. Bard in the second quarter valued at about $265,663,000. Pentwater Capital Management LP acquired a new position in shares of C.R. Bard in the second quarter valued at about $139,088,000. York Capital Management Global Advisors LLC acquired a new position in shares of C.R. Bard in the second quarter valued at about $122,678,000. Finally, CNH Partners LLC acquired a new position in shares of C.R. Bard in the second quarter valued at about $116,100,000. Hedge funds and other institutional investors own 79.11% of the company’s stock.

Shares of C.R. Bard (BCR) opened at $333.19 on Thursday. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.57. The company has a market cap of $24,220.00, a price-to-earnings ratio of 43.90, a PEG ratio of 2.54 and a beta of 0.52. C.R. Bard has a 1 year low of $221.75 and a 1 year high of $337.73.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be issued a $0.26 dividend. The ex-dividend date is Thursday, December 7th. This represents a $1.04 annualized dividend and a dividend yield of 0.31%. C.R. Bard’s dividend payout ratio is currently 10.28%.

TRADEMARK VIOLATION WARNING: This report was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/12/28/analysts-anticipate-c-r-bard-inc-bcr-will-post-earnings-of-3-09-per-share.html.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Get a free copy of the Zacks research report on C.R. Bard (BCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard and related companies with MarketBeat.com's FREE daily email newsletter.